Cov19/ Flua/ Flub Antigen Combo Rapid Test Kit (Colloidal Gold Method)

FOB Price 0.6 - 1.5 USD / pieces

MOQ	100 pieces
Port	Hong Kong
Packaging	tbd
Lead Time	7-15

Product Details

[Product Name]

COV19/ FluA/ FluB Antigen Combo Rapid Test Kit (Colloidal Gold Method)

[Packing Specifications]

1 Test/box;2 Test/box;5 Test/box;25 Test/box

[Intended Use]

The kit is an in vitro immunochromatographic assay for the qualitative detection of Cov19, Influenza A and Influenza B virus antigens in human nasopharyngeal, oropharyngeal swab, and salvia samples.

Cov19 is an acute respiratory infectious disease that humans are easily infected with. According to current epidemiological investigations, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main symptoms are: fever, fatigue, dry cough, in a few cases can appear nasal congestion, sore throat, myalgia and diarrhea. Influenza, often called "the flu," is caused by the influenza virus. It is a highly contagious viral infection of the respiratory tract that can be spread by coughing or sneezing. Influenza outbreaks occur every fall and winter. There are influenza A, B and C viruses. Influenza A viruses are more prevalent than influenza B and Cand causes more severe illness.

Cov19 infection and Influenza virus infection have similar symptoms, such as fever, cough, etc. This kit can simultaneously detect the antigens of the three viruses and provides an easy workflow, short turnaround time, and rapid diagnosis of Cov19, Influenza A and influenza B virus infections using nasopharyngeal, oropharyngeal swab or salvia samples.

[Detection Principle]

The kit is an immunochromatographic assay,based on double antibody sandwich method to detect Cov19 and Influenza A/B virus antigens. This method does not require expensive medical instruments and consumables. After adding the extracted specimen to the sample well on the test cassette, Cov19, Influenza A/B virus antigens in the sample will interact with the colloidal gold-labeled anti-Cov19 and Influenza A/B antibodies on the conjugate pads. Then the conjugate pad will release re-solubilized conjugate onto the nitrocellulose membrane. The nitrocellulose membrane (NC membrane) diffuses it forward.

As the sample moves along the device binding reagents situated on the nitrocellulose membrane bind to the target at the test line. If the sample contains a COV19 antigen, it will bind to the colloidal goldanti-Cov19 Np monoclonal antibody, diffuse forward, and then react with the anti-Cov19 Np monoclonal antibody immobilized on the NC membrane detection line (COV19 Test line). Similarly, if the specimen contains Influenza A/Influenza B antigens, the antigens will react with antibody-coated particles, the conjugate migrate laterally forward, and cause a colored lines (A, B linesrespectively).

On the contrary, if there is no Cov19, Influenza A/B virus antigen in the sample or the concentration of the antigens is below the minimum detection limit, there is no colored lines in the test area and the result is considered to be negative.

As a procedure control, there is a quality control line (C line), this line will always appear in the control line region, indicating that the proper volume of specimen has been added and membrane wicking has occurred, otherwise the test result is invalid.